Market Place
Sourcing Support
Pieris Announces Strategy to Maximize Partnered Milestone and Royalty Potential
27 Mar 2024 //
ACCESSWIRE
Pieris lays off 70% of staff after AstraZeneca axes collab
19 Jul 2023 //
FIERCE BIOTECH
Pieris completes safety review of 10mg dose in asthma drug Phase IIa trial
05 May 2023 //
CLINICAL TRIALS ARENA
Pieris puts phase 2 cancer drug out on chopping block
05 Aug 2022 //
FIERCEBIOTECH
Pieris doses first subject in Phase II gastric cancer drug trial
17 Jan 2022 //
CLINICALTRIALSARENA
Pieris Pharma Announces First Patient Dosed Phase 2 Gastric Cancer
14 Jan 2022 //
TRIALSITENEWS
Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer
06 Oct 2021 //
BIOSPACE
Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS
24 Aug 2021 //
PRESS RELEASE
Pieris Pharma Announces Respiratory and Ophthalmology Collab with Genentech
26 May 2021 //
PRESS RELEASE
Pieris and Boston Enter into an Exclusive Worldwide Product License for PRS-342
26 Apr 2021 //
BUSINESSWIRE
Pieris and Boston Enter into an Exclusive Worldwide Product License for PRS-342
26 Apr 2021 //
BUSINESSWIRE
PIERIS ANNOUNCES AMENDMENT OF EXISTING IMMUNO-ONCOLOGY MULTI-TARGET
25 Mar 2021 //
PIERIS
Pieris finally vaults FDA hold on next-gen solid tumor hunter, clearing the path
21 Jan 2021 //
ENDPTS
PIERIS & LILLY ENTER INTO A CLINICAL TRIAL COLLABORATION TO EVALUATE OF PRS-343
10 Aug 2020 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.